SG11202105743RA - Methods for treating or preventing gout or hyperuricemia - Google Patents
Methods for treating or preventing gout or hyperuricemiaInfo
- Publication number
- SG11202105743RA SG11202105743RA SG11202105743RA SG11202105743RA SG11202105743RA SG 11202105743R A SG11202105743R A SG 11202105743RA SG 11202105743R A SG11202105743R A SG 11202105743RA SG 11202105743R A SG11202105743R A SG 11202105743RA SG 11202105743R A SG11202105743R A SG 11202105743RA
- Authority
- SG
- Singapore
- Prior art keywords
- hyperuricemia
- treating
- methods
- preventing gout
- gout
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Physiology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Furan Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862776251P | 2018-12-06 | 2018-12-06 | |
| PCT/US2019/064785 WO2020118114A1 (en) | 2018-12-06 | 2019-12-05 | Methods for treating or preventing gout or hyperuricemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202105743RA true SG11202105743RA (en) | 2021-06-29 |
Family
ID=70974386
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202105743RA SG11202105743RA (en) | 2018-12-06 | 2019-12-05 | Methods for treating or preventing gout or hyperuricemia |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12419854B2 (enExample) |
| EP (1) | EP3890722A4 (enExample) |
| JP (1) | JP7528080B2 (enExample) |
| KR (1) | KR102956127B1 (enExample) |
| CN (1) | CN113164439A (enExample) |
| AU (1) | AU2019392750B2 (enExample) |
| BR (1) | BR112021010720A2 (enExample) |
| CA (1) | CA3121624A1 (enExample) |
| EA (1) | EA202191543A1 (enExample) |
| IL (1) | IL283665A (enExample) |
| SG (1) | SG11202105743RA (enExample) |
| TW (1) | TW202038936A (enExample) |
| WO (1) | WO2020118114A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201900405XA (en) | 2016-07-18 | 2019-02-27 | Arthrosi Therapeutics Inc | Compounds, compositions and methods for treating or preventing a sympton associated with gout or hyperuricemia |
| KR102946486B1 (ko) | 2018-12-06 | 2026-03-31 | 아쓰로시 테라퓨틱스, 인크. | 통풍 또는 고뇨산혈증의 치료 또는 예방을 위한 화합물의 결정형 |
| WO2020118114A1 (en) | 2018-12-06 | 2020-06-11 | Arthrosi Therapeutics, Inc. | Methods for treating or preventing gout or hyperuricemia |
| CN113368032A (zh) * | 2020-07-23 | 2021-09-10 | 太阳升(亳州)生物医药科技有限公司 | 药物组合物、口服固体制剂及其制备方法和用途 |
| TW202330485A (zh) * | 2021-12-02 | 2023-08-01 | 美商安索治療公司 | 用於治療或預防痛風或高尿酸血症之化合物的結晶形式 |
| US20250100988A1 (en) * | 2021-12-30 | 2025-03-27 | Arthrosi Therapeutics, Inc. | Preparation of a compound for the treatment of gout or hyperuricemia |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
| US4624848A (en) | 1984-05-10 | 1986-11-25 | Ciba-Geigy Corporation | Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use |
| US4968509A (en) | 1987-07-27 | 1990-11-06 | Mcneilab, Inc. | Oral sustained release acetaminophen formulation and process |
| IL92966A (en) | 1989-01-12 | 1995-07-31 | Pfizer | Dispensing devices powered by hydrogel |
| AU1537292A (en) | 1991-04-16 | 1992-11-17 | Nippon Shinyaku Co. Ltd. | Method of manufacturing solid dispersion |
| AU661080B2 (en) | 1991-11-22 | 1995-07-13 | Warner Chilcott Company, Llc | Risedronate delayed-release compositions |
| US5461140A (en) | 1992-04-30 | 1995-10-24 | Pharmaceutical Delivery Systems | Bioerodible polymers for solid controlled release pharmaceutical compositions |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| KR100291362B1 (ko) | 1992-10-16 | 2001-09-17 | 니뽄 신야쿠 가부시키가이샤 | 왁스매트릭스의제법 |
| US5686105A (en) | 1993-10-19 | 1997-11-11 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery |
| EP0827402A2 (en) | 1995-05-17 | 1998-03-11 | Cedars-Sinai Medical Center | Compositions containing fatty acids for improving digestion and absorption in the small intestine |
| DE19624292A1 (de) | 1996-06-18 | 1998-01-02 | Merckle Gmbh | Verfahren und Zwischenprodukte zur Herstellung von 1'-Hydroxybenzbromaron |
| US6395300B1 (en) | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
| US6465014B1 (en) | 2001-03-21 | 2002-10-15 | Isp Investments Inc. | pH-dependent sustained release, drug-delivery composition |
| JP4814789B2 (ja) | 2004-06-10 | 2011-11-16 | 鳥居薬品株式会社 | ６−ヒドロキシベンズブロマロン又はその塩からなる医薬組成物 |
| US20080305169A1 (en) | 2006-05-26 | 2008-12-11 | Japan Tobacco Inc. | Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds |
| CN101765582A (zh) | 2007-04-26 | 2010-06-30 | 奥斯拜客斯制药有限公司 | 氘标记的氯胺酮 |
| BRPI0913129A2 (pt) * | 2008-05-22 | 2016-01-05 | Bristol Myers Squibb Co | método para tratamento de hiperuricemia empregando um inibidor de sglt2 e composição contendo o mesmo |
| JP5325065B2 (ja) | 2009-09-30 | 2013-10-23 | 株式会社富士薬品 | 新規フェノール誘導体 |
| IT1400609B1 (it) * | 2010-05-10 | 2013-06-14 | Menarini Int Operations Lu Sa | Associazione di inibitori della xantina ossidasi e metformina e loro uso. |
| JP5844376B2 (ja) | 2010-10-06 | 2016-01-13 | ジェイファーマ株式会社 | 強力な尿酸トランスポーター阻害剤の開発：それらの尿酸排泄効果のために設計された化合物 |
| US20150031768A1 (en) | 2011-08-19 | 2015-01-29 | The Trustees Of Princeton University | C-halogen bond formation |
| US9060987B2 (en) | 2011-11-04 | 2015-06-23 | Cymabay Therapeutics, Inc. | Methods for treating gout flares |
| US9962362B2 (en) * | 2012-03-29 | 2018-05-08 | Children's Hospital Medical Center | Use of small molecule inhibitors targeting EYA tyrosine phosphatase |
| WO2013152860A2 (en) | 2012-04-11 | 2013-10-17 | Dutalys Gmbh | Improved antibody light chains |
| WO2013184572A1 (en) | 2012-06-04 | 2013-12-12 | Pharmacyclics, Inc. | Crystalline forms of a bruton's tyrosine kinase inhibitor |
| JP6664219B2 (ja) | 2012-08-14 | 2020-03-13 | ミネルバ バイオテクノロジーズ コーポレーション | 幹細胞増強治療法 |
| BR112015013020A2 (pt) | 2012-12-05 | 2017-07-11 | Dutalys Gmbh | método de geração de anticorpos biespecíficos, coleção de anticorpos ou seus fragmentos funcionais, de sequências de ácidos nucleicos, de vetores e de células hospedeiras, método de produção da coleção de anticorpos e de identificação de um anticorpo, anticorpo ou fragmento funcional e anticorpo biespecífico |
| WO2014113407A2 (en) * | 2013-01-16 | 2014-07-24 | Children's Hospital Medical Center | Use of small molecule inhibitors targeting eya tyrosine phosphatase |
| EP2968235B1 (en) * | 2013-03-15 | 2017-09-13 | Janssen Pharmaceutica NV | Combination of canagliflozin and probenecid for the treatment of hyperuricemia |
| US20140357683A1 (en) | 2013-05-31 | 2014-12-04 | Takeda Pharmaceuticals U.S.A., Inc. | Methods of treatment and compositions with xanthine oxidase inhibitors |
| WO2015134467A1 (en) | 2014-03-05 | 2015-09-11 | The Trustees Of Princeton University | Methods and compositions for direct radioactive labeling of bio-active molecules and building blocks |
| JP6571756B2 (ja) | 2014-07-31 | 2019-09-04 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | 神経変性疾患に適応可能なインドリジン誘導体 |
| CN104262305B (zh) | 2014-09-16 | 2016-06-08 | 东北制药集团股份有限公司 | 一种苯溴马隆晶型a及其制备方法 |
| CN104311516B (zh) | 2014-09-16 | 2017-01-11 | 东北制药集团股份有限公司 | 一种苯溴马隆晶型b及其制备方法 |
| SG11201900405XA (en) * | 2016-07-18 | 2019-02-27 | Arthrosi Therapeutics Inc | Compounds, compositions and methods for treating or preventing a sympton associated with gout or hyperuricemia |
| WO2018090921A1 (zh) | 2016-11-16 | 2018-05-24 | 江苏新元素医药科技有限公司 | Urat1抑制剂及其应用 |
| CN109415333B (zh) | 2016-12-14 | 2022-07-12 | 株式会社Lg化学 | 杂环化合物及包含其的有机发光元件 |
| US20210130312A1 (en) | 2018-04-03 | 2021-05-06 | Children's Hospital Medical Center | Inhibitors of eya3-protein tyrosine phosphatase in dna damage repair signaling of pulmonary arterial hypertension |
| BR112021006002A2 (pt) | 2018-10-01 | 2021-06-29 | Astrazeneca Ab | composições para a redução de ácido úrico sérico |
| KR102946486B1 (ko) | 2018-12-06 | 2026-03-31 | 아쓰로시 테라퓨틱스, 인크. | 통풍 또는 고뇨산혈증의 치료 또는 예방을 위한 화합물의 결정형 |
| WO2020118114A1 (en) | 2018-12-06 | 2020-06-11 | Arthrosi Therapeutics, Inc. | Methods for treating or preventing gout or hyperuricemia |
| SG11202112562XA (en) | 2019-05-14 | 2021-12-30 | Arthrosi Therapeutics Inc | Compound for treating gout or hyperuricemia |
| CN112952564B (zh) | 2019-12-25 | 2022-04-22 | 华为数字能源技术有限公司 | 配电模块及通信电源系统 |
| AU2021288679A1 (en) | 2020-06-10 | 2023-02-02 | Arthrosi Therapeutics, Inc. | Methods for treating or preventing chronic kidney disease |
| CN112729156A (zh) | 2020-12-24 | 2021-04-30 | 上海智能制造功能平台有限公司 | 一种人体数字化测量装置的数据拼接及系统标定方法 |
| CN114697265A (zh) | 2020-12-29 | 2022-07-01 | 华为技术服务有限公司 | 一种报文处理方法及装置 |
| TW202330485A (zh) | 2021-12-02 | 2023-08-01 | 美商安索治療公司 | 用於治療或預防痛風或高尿酸血症之化合物的結晶形式 |
| US20250100988A1 (en) | 2021-12-30 | 2025-03-27 | Arthrosi Therapeutics, Inc. | Preparation of a compound for the treatment of gout or hyperuricemia |
-
2019
- 2019-12-05 WO PCT/US2019/064785 patent/WO2020118114A1/en not_active Ceased
- 2019-12-05 CA CA3121624A patent/CA3121624A1/en active Pending
- 2019-12-05 KR KR1020217021179A patent/KR102956127B1/ko active Active
- 2019-12-05 EP EP19891796.5A patent/EP3890722A4/en active Pending
- 2019-12-05 CN CN201980080586.8A patent/CN113164439A/zh active Pending
- 2019-12-05 BR BR112021010720-7A patent/BR112021010720A2/pt unknown
- 2019-12-05 US US17/311,245 patent/US12419854B2/en active Active
- 2019-12-05 AU AU2019392750A patent/AU2019392750B2/en active Active
- 2019-12-05 EA EA202191543A patent/EA202191543A1/ru unknown
- 2019-12-05 JP JP2021531034A patent/JP7528080B2/ja active Active
- 2019-12-05 SG SG11202105743RA patent/SG11202105743RA/en unknown
- 2019-12-06 TW TW108144816A patent/TW202038936A/zh unknown
-
2021
- 2021-06-02 IL IL283665A patent/IL283665A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210102933A (ko) | 2021-08-20 |
| CN113164439A (zh) | 2021-07-23 |
| AU2019392750B2 (en) | 2025-07-10 |
| IL283665A (en) | 2021-07-29 |
| EA202191543A1 (ru) | 2021-10-26 |
| CA3121624A1 (en) | 2020-06-11 |
| JP2022510303A (ja) | 2022-01-26 |
| AU2019392750A1 (en) | 2021-07-15 |
| US12419854B2 (en) | 2025-09-23 |
| BR112021010720A2 (pt) | 2021-08-31 |
| EP3890722A1 (en) | 2021-10-13 |
| TW202038936A (zh) | 2020-11-01 |
| WO2020118114A1 (en) | 2020-06-11 |
| EP3890722A4 (en) | 2022-08-24 |
| US20220023251A1 (en) | 2022-01-27 |
| JP7528080B2 (ja) | 2024-08-05 |
| KR102956127B1 (ko) | 2026-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL283665A (en) | Methods for treating or preventing rheumatism or hyperuricemia | |
| ZA202105643B (en) | Processes and compounds | |
| PT3348557T (pt) | Imidazo[1,2a]piridinas para o tratamento ou prevenção de hiperuricemia ou gota | |
| IL291687A (en) | Methods for treating myelofibrosis and related conditions | |
| PT3484862T (pt) | Compostos, composições e métodos para o tratamento ou a prevenção de um sintoma associado a gota ou hiperuricemia | |
| SG11202112562XA (en) | Compound for treating gout or hyperuricemia | |
| GB201813876D0 (en) | Treatment | |
| IL283663A (en) | Crystalline forms of a compound for the treatment or prevention of rheumatism or hyperuricemia | |
| GB2589217B (en) | At-the-bit mud loss treatment | |
| ZA201907973B (en) | Agent for preventing or treating brain atrophy | |
| SG11202012055PA (en) | Methods and compositions for preventing or treating calciphylaxis | |
| ZA201907975B (en) | Agent for preventing or treating tauopathy | |
| LT4034122T (lt) | Hiperfenilalaninemijos gydymo būdai | |
| GB201800546D0 (en) | Treatment | |
| PL3638630T3 (pl) | Sposób obróbki szlamu | |
| SG11202102416SA (en) | Methods for treating pancreatitis | |
| SG11202102878TA (en) | Treatment methods | |
| SG11202102827YA (en) | Treatment methods | |
| IL284668A (en) | Methods of treating schizophrenia | |
| PL3431656T3 (pl) | Sposób obróbki kamieni tłuczniowych | |
| ZA202001536B (en) | Method for the treatment of wastewaters | |
| SG11202104111UA (en) | Floating facility | |
| SG10201910408QA (en) | Device for treating dysarthrosis | |
| GB201804763D0 (en) | Gout treatment | |
| IL278984A (en) | Spinamide for the treatment of muscle deformity |